Irisin, a myokine released during exercise, promotes browning of subcutaneous adipose tissue and regulates energy homeostasis. Although exercise constantly reduces blood cholesterol, whether irisin is involved in the regulation of cholesterol remains largely unknown. In the present study, subcutaneous infusion of irisin for 2 weeks induced a reduction in plasma and hepatic cholesterol in high fat diet-induced obese (DIO) mice. These alterations were associated with an activation of 5′ AMP-activated protein kinase (AMPK) and inhibition of sterol regulatory element-binding transcription factor 2 (SREBP2) transcription and nuclear translocation. In primary hepatocytes from either lean or DIO mice, irisin significantly decreased cholesterol content via sequential activation of AMPK and inhibition of SREBP2. Suppression of AMPK by compound C or AMPKα1 siRNA blocked irisininduced alterations in cholesterol contents and SREBP2. In conclusion, irisin could suppress hepatic cholesterol production via a mechanism dependent of AMPK and SREBP2 signaling. These findings suggest that irisin is a promising therapeutic target for treatment of hypercholesterolemia.
Introduction
Irisin was recently identified as a myokine proteolytically cleaved from fibronectin type β domain containing 5 (FNDC5) . Exercise could induce irisin expression and secretion into circulation to exert its effects on browning of subcutaneous adipose tissue Wu et al., 2014; Shan et al., 2013; Rodriguez et al., 2015; Lee et al., 2014; Wu et al., 2012) , as well as subsequent improvement of obesity (Huh et al., 2014; Miyamoto-Mikami et al., 2015) and its related disorders such as type 2 diabetes (Xiong et al., 2015; Bostrom et al., 2012; Vaughan et al., 2014) . These observations suggest that irisin may contribute to the regulation of energy homeostasis and thus is the potential target for therapy of metabolic dysfunction associated with obesity. This concept is further supported by clinical observations. Circulating irisin was found to be reduced in obese human (Yan et al., 2014; Moreno-Navarrete et al., 2013; Duran et al., 2015; Hou et al., 2015) and rodents (Bilski et al., 2015) and in patients with diabetes (Espes et al., 2015; Li et al., 2015a; Choi et al., 2013; Xiang et al., 2014; Liu et al., 2013; Duran et al., 2015; Moreno-Navarrete et al., 2013; Kurdiova et al., 2014) , or chronic kidney disease (Wen et al., 2013; Ebert et al., 2014) . Conversely, it was positively associated with endothelium-dependent vasodialation (Xiang et al., 2014; Hou et al., 2015; Zhu et al., 2015) and myocardiac infraction in type 2 diabetes (Aronis et al., 2015; Hou et al., 2015) .
The relationship between irisin and lipid metabolism has been controversial. Evidence suggesting a negative relation between irisin and lipid dysregulation has been emerging. Circulating levels of irisin were negatively correlated with total cholesterol, LDL cholesterol and triglyceride (Huh et al., 2012; Zhang et al., 2013; Ebert et al., 2015; Duran et al., 2015) and intrahepatic triglyceride contents in obese adults (Zhang et al., 2013) , while positively correlated with HDL cholesterol. In obese human, diet intervention-induced reduction in glucose and triglyceride was greater in those with higher baseline irisin levels . Lentivirus-mediated overexpression of FNDC5 or subcutaneous perfusion of irisin reduced blood triglyceride, cholesterol, free fatty acid and glucose in obese mice (Xiong et al., 2015) . Further studies in vitro showed an inhibitory effect of irisin on palmitic acid (PA)-induced lipid accumulation and lipogenic markers via inhibition of protein arginine methyltransferase-3 in AML12 cells and mouse primary hepatocytes . Other studies have suggested a positive relation between irisin and lipid dysfunction. Circulating irisin levels were positively associated with total cholesterol, LDL cholesterol and fasting fatty acids in a Chinese population independent of BMI and in women with polycystic ovary syndrome . Energy restriction induced depletion of irisin was associated with decrease in total cholesterol, total cholesterol/HDL-cholesterol ratio, LDL-cholesterol and apolipoprotein B, independent of changes in body weight . In adults at higher cardiovascular risk, irisin was negatively associated with HDL cholesterol and large HDL particles (Panagiotou et al., 2014) . In addition, serum irisin was significantly higher in patients with nonalcoholic fatty liver disease (Choi et al., 2014) and in patients with portal inflammation (Polyzos et al., 2014) . Moreover, plasma irisin was positively related to total cholesterol in adults with Prader-Willi Syndrome (Hirsch et al., 2015) . Nevertheless, other studies have found no significant association of irisin with raised triglyceride and reduced HDL in obese adults with metabolic syndrome (Yan et al., 2014) or with NAFLD . In addition, irisin has been demonstrated to exercise no effect on either lipolysis in 3T3-L1 adipocytes or fatty acid metabolism in HepG2 hepatocytes . Therefore, further investigation is necessary to define the role of irisin in lipid metabolism.
Here we reported that irisin suppressed cholesterol synthesis in hepatocytes through the activation of 5′ AMP-activated protein kinase (AMPK) and subsequent inhibition of transcription and nuclear translocation of sterol regulatory element-binding transcription factor 2 (SREBP2).
Materials and Methods

Materials
Antibodies used in the study were: pAMPKα Thr172 (2535, CST, Beverly, MA, USA) and AMPKα (2532, CST), SREBP2 (ab30682, Abcam, Cambridge, MA, USA) and β-actin (AT 0001, Milwaukee, WI). Donkey-anti-rabbit Alexa Fluor® 488-IgG (711-545-152) was from Jackson ImmunoResearch (West Grove, PA, USA). IRDyeconjugated affinity purified anti-rabbit and anti-mouse IgGs were purchased from Rockland (Gilbertsville, PA, USA). Irisin (067-16) was from Pheonix (Burlingame, CA, USA). Recombinant irisin-Fc and Fc control were expressed in HEK293 cells (Abgent, Nanjing, China) and purified by high-performance liquid chromatography. Oleic acid (OA), collagenase IV and compound C were purchased from Sigma Aldrich (St. Louis, MO, USA). Alzet microosmotic pumps (1002) were from DURECT Corporation (Cupertino, CA, USA). Aprotinin was purchased from Amersham Biosciences (Pittsburgh, PA, USA). Triglyceride and cholesterol Colorimetric Assay Kits were from Cayman Chemical Company (Ann Arbor, MI, USA). BCA protein quantitative assay kit was from Applied Gene (Beijing, China).
Animals
Animals were handled in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23, revised 1996) . All experimental protocols were approved by the Animal Care and Use Committee of Peking University. Mice were housed in standard plastic rodent cages and maintained in a regulated environment (24°C, 12-h light and 12-h dark cycle with lights on at 7 AM and off at 7 PM). Four-week-old male C57BL/6J mice were fed a normal chow diet (NCD) or a high-fat diet (HFD) (60% fat, D12492; Research Diets, New Brunswick, NJ, USA) ad libitum for 14 weeks followed by 2-week subcutaneous perfusion of irisin-Fc or Fc control at a dose of 12 nmol/d·kg body weight (BW). Food intake was measured and averaged for 2 mice in one cage. Mice were sacrificed without fasting after anesthesia by intraperitoneal injection of pentobarbital sodium at 70 mg/kg BW. Liver was frozen in liquid nitrogen and stored in − 80°C freezer for future experiments. Blood samples were transcardially collected and immediately transferred to chilled polypropyrene tubes containing EDTA-Na 2 (12.5 mg/mL) and aprotinin (1000 units/mL) and centrifuged at 4°C. The plasma was separated and stored at − 80°C before use.
Implantation of Osmotic Minipumps
The minipumps were placed in a Petri dish with sterile 0.9% saline at 37°C for at least 4 h, then filled with the test agent before implantation. Mice were anesthetized with pentobarbital sodium and a 1 cm incision was made in the back skin through which an Alzet osmotic minipump (model 1002) filled with irisin-Fc or Fc control was implanted subcutaneously.
Isolation and Culture of Primary Hepatocytes
Twelve-week old lean or diet-induced-obese (DIO) C57BL/6J mice were anesthetized with pentobarbital sodium at 60 mg/kg BW and injected intraperitoneally with 1000 IU heparin. After laparotomy, the portal vein was cannulated. The liver was perfused with 20 mL of pre-warmed 37°C Hanks buffer, followed by 20 mL of 0.02% collagenase IV at a flow rate of 2 mL/min. After perfusion, liver tissues were removed and washed with warm Hanks buffer. Liver capsule was removed, and hepatic tissues dispersed and incubated in 20 mL of 0.01% collagenase IV in a shaking water bath at 37°C for 20 min. Cell suspension was then filtered through 80-μm nylon mesh twice, centrifuged at 500 rpm [SorvallRT7 Benchtop Centrifuge with RTH 250 rotor (Ramsey, MN)] and washed twice with DMEM to remove tissue dissociation enzymes, damaged cells, and nonparenchymal cells. Dispersed hepatocytes were counted and seeded at a concentration of 1-2 × 10 5 cells per well in a 6-well plate containing 2 mL of high glucose DMEM supplemented with 10% (vol/vol) FBS. Cells were cultured at 37°C in a humidified atmosphere of 5% (vol/vol) CO 2 . Culture medium was changed to high glucose DMEM supplemented with 2% (vol/vol) FBS 24 h later. Hepatocytes were then treated with 10 nM irisin for 20 min or 3, 6, 12 and 24 h as indicated in the absence or presence of 125 μM OA. Where indicated, compound C was added 1 h prior to the addition of irisin and OA.
Cell Culture and siRNA Transfection
HepG2 cells were cultured with high glucose DMEM supplemented with 10% (vol/vol) FBS at 37°C in a humidified atmosphere of 5% (vol/ vol) CO 2 . Cells were seeded in a 12-well plate at 30-50% confluency. siRNA was transfected using siRNA-Mate (G04002, GenePharma, Shanghai, China) following the manufacturer's instructions. Culture medium was changed to high glucose DMEM supplemented with 2% (vol/ vol) FBS 48 h later. Cells were stimulated with 10 nM irisin for 12 h or 24 h as indicated. siRNA sequences were for Scrambled sense: 5′-UUCUCCGAACGUGUCACGUTT-3′, antisense: 5′-ACGUGACACGUUCG GAGAATT-3′; for siAMPKα1 sense: 5′-CGGGAUCAGUUAGCAACUATT-3′, antisense: 5′-UAGUUGCUAACUGAUCCCGTT-3′.
Measurements of Triglyceride and Cholesterol Content
Twenty milligram liver tissues were homogenized in 1 mL of 2:1 chloroform/methanol mix on ice and placed at 4°C for 18 h. Two hundred microliters of distilled water was added to the homogenates. The mixture was vortexed, then centrifuged for 10 min at 3000 rpm, 4°C. The lower phase was collected, lyophilized and resolved in 5% Triton X-100 in PBS for measurements of lipids. Primary hepatocytes were homogenated according to manufacturer's instructions, and the supernatant was used for lipid detection. Plasma, hepatic and primary hepatocytes triglyceride and cholesterol were measured according to the manufacturer's instructions. Values were normalized to protein concentration.
Western Blot Analysis
Liver tissues and primary hepatocytes were homogenized in RIPA lysis buffer. Proteins were subjected to SDS/PAGE separation with a 8-10% running gel, then transferred to a nitrocellulose membrane. Membranes were incubated for 1 h at room temperature with 5% fat-free milk in Tris-buffered saline containing Tween 20, followed by incubation overnight at 4°C with primary antibodies. Specific reaction was detected by using IRDye-conjugated second antibody and visualized using the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA).
Gene Expression Analysis
For analyses of gene expression, RNA was extracted from mouse liver or primary hepatocytes using RNATrip (Applied Gene, Beijing, China) and reverse-transcribed into cDNAs using the First-Strand Synthesis System for RT-PCR kit (Fermentas, Lafayette, CO, USA). SYBR Green-based quantitative real time-PCR was performed using the Mx3000 multiplex quantitative PCR system (Stratagene, La Jolla, CA, USA). Triplicate samples were collected for each experiment to determine relative expression levels. All gene expression levels were normalized by β-actin. Sequences for the primer pairs used in this study are listed in Supplemental Table 1 .
Immunofluorescent Staining
Liver frozen sections and isolated hepatocytes were washed with PBS three times and fixed in 4% paraformaldehyde for 20 min, followed by permeabilization with 0.05% Triton X-100 in PBS for 20 min. Nonspecific binding were blocked by 4% goat serum for 1 h. Liver slides or hepatocytes were then incubated with anti-SREBP2 (1:100) overnight at 4°C. After 3-time wash in PBS, the liver slides or hepatocytes were incubated with anti-rabbit Alex fluor488-conjugated IgG (1:500) at room temperature for 1 h followed by incubation of Hoechst for 15 min. Fluorescent signals were observed and captured under a confocal laserscanning microscope (Leica). The signal intensity was analyzed by software Leica Qwin 2.6.
Nuclear Fraction Extraction
Primary hepatocytes cultured in a 6-well plate were washed twice with cold PBS and collected in 100 μL of 1× hypotonic buffer containing 20 mM Tris-HCl of pH 7.4, 10 mM NaCl and 3 mM MgCl 2 followed by incubation on ice for 15 min. Five microliter detergent (10% NP40) was added and vortexed for 10 s, then centrifuged for 10 min at 3000 rpm at 4°C. The supernatant contained the cytoplasmic fraction. The remained nuclear pellets were re-suspended in 50 μL cell extraction buffer (containing 100 mM Tris-HCl of pH 7.4, 2 mM Na 3 VO 4 , 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 10% glycerol, 1 mM EGTA, 0.1% SDS, 1 mM NaF, 0.5% deoxycholate and 20 mM Na 4 P 2 O 7 ) presupplemented with 1 mM PMSF and protease inhibitor cocktail and ultrasonicated, followed by centrifugation for 30 min at 14,000 g, 4°C. Supernatant was collected as the nuclear fraction.
Fast-protein Liquid Chromatography Fractionation of Lipoproteins
Two hundredmicroliter of plasma aliquots were pooled from 6 mice per group and applied to Tricorn high-performance Superose S-6 10/ 300 GL columns using a fast-protein liquid chromatography system (Amersham Biosciences, Marlborough, MA, USA), followed by elution with FPLC buffer (pH 7.4, containing 8.775 g NaCl, 3.58 g Na 2 HPO 4 ·12H 2 O and 37.2 g EDTA in 1 L distilled water) at a constant flow rate of 0.75 mL/min. Eluted fractions (500 μL) were assayed for triglyceride and cholesterol concentrations.
Oil Red O Staining
Liver frozen sections were rinsed in PBS three times, then fixed with 4% paraformaldehyde for 10 min. After washing, slices were incubated in 0.3% oil-red staining solution for 1 h at room temperature. Samples were then counterstained with hematoxylin for 30 s, followed by wash in running water for 60 min. All slides were mounted with 90% glycerol and stored at 4°C before observation. The signal intensity was analyzed by software QWin 2.6.
Glucose Tolerance Test and Insulin Tolerance Test
For oral glucose tolerance tests, mice were fasted for 16 h followed by intragastric administration of glucose (3 g/kg BW) by gavage. For insulin tolerance tests, mice were fasted for 6 h, followed by intraperitoneal injection of insulin (1 IU/kg BW). Blood was drawn from the tail vein at 0, 15, 30, 60, 90 and 120 min, and blood glucose concentrations were detected immediately.
Statistical Analysis
All data are expressed as mean ± SEM. Statistical difference was determined by Student's t test or two-way ANOVA and post-hoc Bonferroni test. P b 0.05 was considered significant. 
Results
Amelioration of Obesity by Irisin
Four-week-old C57 BJ/L6 mice were fed NCD or HFD for 16 weeks. During the last 2 weeks, irisin was infused into mice subcutaneously at a dose of 12 nmol/d·kg BW via an osmotic pump. As shown in Fig.  1 , irisin decreased body weight of DIO mice relative to animals receiving vehicle control (Fig. 1a) , while demonstrated no effect on food intake (Fig. 1b) . Organ mass for liver, epididymal white adipose tissue (eWAT) and subcutaneous WAT (sWAT) was also decreased by irisin in DIO mice (Fig. 1c) . The reduction in WAT mass was associated with a decrease in the size of adipocytes in eWAT and sWAT, especially in the DIO group (Fig. 1d) , as well as induction of multilocular lipid droplets in adipocytes in animals fed NCD (Fig. 1d ). Interestingly, glucose intolerance in DIO mice was ameliorated by irisin, whereas insulin sensitivity remained unaltered (Fig. 1e ).
Effect of Irisin on Plasma and Hepatic Cholesterol Contents
Since irisin improved adiposity in mice, we next examined the change of lipid levels. As shown in Fig. 2 , irisin significantly decreased plasma total, VLDL-, LDL-, HDL-cholesterol, and hepatic levels of total and esterified cholesterol in DIO mice, while demonstrated no consistent effect on plasma and hepatic triglyceride ( Fig. 2a, b) . Consistently, Oil red O staining showed reduced fat deposition in hepatocytes in mice treated with irisin relative to the control (Fig. 2c) . Histological examination demonstrated a significant reduction of vacuolation in the liver of DIO mice (Fig. 2d) . Similar results were observed for synthetic irisin (Supplemental Fig. 1 ). Collectively, irisin reduced plasma and hepatic cholesterol contents in DIO mice.
Effect of Irisin on Cholesterol Metabolism Related Genes in Mouse Liver
Genes related to lipid synthesis, transport and degradation in the liver were next determined. As shown in Fig. 3a , mRNA levels of SREBP2 (Srebf2), 3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr), 3-hydroxy-3-methylglutaryl-Coenzyme A synthase (Hmgcs) and the liver X receptor α (LXRα, Nr1h3)), which are all important in cholesterol synthesis, were significantly decreased by irisin treatment. In addition, peripheral infusion of irisin significantly suppressed mRNA levels of low density lipoprotein receptor (Ldlr) that recognizes and uptakes LDL-cholesterol, while increased mRNA levels of ATP-binding cassette gene 5 (Abcg5) and Abcg8 which form a heterodimer to mediate cholesterol secretion (Fig. 3b ). No significant effect was observed for Cyp7a1 and Cyp8b1 which are critical for bile acid synthesis from cholesterol (Fig. 3b ). Further, no change in Fgf21 mRNA expression (Supplemental Fig. 2a ) and AKT phosphorylation (Supplemental Fig. 2b ) were detected after irisin infusion. As for genes related to triglyceride metabolism, irisin demonstrated only modest inhibition for triglyceride synthesisrelated genes such as SREBP1c (Srebf1c), glycerol-3-phosphate acyltransferase (Gpam), and diacylglycerol O-acyltransferase 1 (Dgat1) (Fig. 3c) . mRNA levels of genes critical for fatty acid synthesis including acetyl-Coenzyme A carboxylase alpha (Acaca), fatty acid synthase (Fasn), and stearoyl-Coenzyme A desaturase 1 (Scd1), and β-oxidation such as peroxisome proliferator-activated receptor α (Pparα) and carnitine palmitoyltransferase 1A (Cpt1α) remained unchanged (Fig. 3d) . Therefore, irisin decreased mRNA expression of genes related to the synthesis of cholesterol, while increased those genes related to cholesterol excretion.
Direct Effects of Irisin on Cholesterol Synthesis in Cultured Primary Hepatocytes
To determine whether irisin directly acts on hepatocytes to regulate cholesterol synthesis, we treated the primary hepatocytes isolated from either lean ( Fig. 4a-d) or DIO ( Fig. 4e-g ) mice with irisin. OA was previously reported to increase cholesterol synthesis and HMGCR activity in hepatocytes (Goh and Heimberg, 1976; Gibbons et al., 1986) . We thus treated the cultured hepatocytes with OA in our experiment. OAinduced increase in cholesterol content was reversed by irisin treatment in primary hepatocytes from either lean (Fig. 4a) or DIO (Fig. 4e ) mice, while no significant change was observed for triglyceride in hepatocytes from DIO mice (Fig. 4e) . We next examined the mRNA expression of genes related to cholesterol metabolism in hepatocytes from lean mice. Consistent with the alteration in mouse liver, mRNA levels of Srebf2, Hmgcr, Hmgcs and Ldlr were decreased by irisin treatment in the presence or absence of OA in cultured hepatocytes (Fig. 4b) . However, mRNA levels of LXRα, Abcg5, Abcg8, Cyp7a1 and Cyp8b1 were not affected (Fig. 4c) . mRNA levels of genes related to triglyceride metabolism including Srebf1c, Dgat1, and Cpt1α were not affected (Fig. 4d) . Similar observation was detected in hepatocytes from DIO mice. mRNA levels of Srebf2, Hmgcr, Hmgcs and LXRα were decreased by treatment of hepatocytes with irisin in the presence or absence of OA (Fig. 4f ). However, genes related to cholesterol uptake (Ldlr, Pcsk9 and ApoB), secretion (Abca1, Abcg5 and Abcg8) and bile acid synthesis (Cyp7a1 and Cyp8b1) remained largely unaltered (Fig. 4g ). Furthermore, conditioned medium from C2C12 myotubes infected with Ad-FNDC5 blocked the OA-induced increment of cholesterol in hepatocytes isolated from either lean or DIO mice, while demonstrated negligible effect on triglyceride (Fig. 4h ). All these results indicated that irisin inhibited the cholesterol synthesis in hepatocytes.
AMPK-SREBP2 Dependent Effects
AMPK-SREBP2 signaling is critical for the regulation of cholesterol metabolism (Quan et al., 2013; Elhanati et al., 2013) . We thus investigated whether this signaling mechanism mediates the suppression of cholesterol synthesis induced by irisin in hepatocytes. As shown in Fig.  5a , irisin at a dose of 10 nM significantly increased the phosphorylation of AMPKα Thr172 in a time-dependent manner. This alteration was associated with a decrease in the nuclear translocation of SREBP2 in hepatocytes isolated from mice fed either NCD (Fig. 5b, c) or HFD (Fig. 5d, e ).
To determine whether AMPK is required for the effects of irisin on cholesterol synthesis in hepatocytes, compound C was used to block the activation of AMPK. As shown in Fig. 6a , treatment of hepatocytes with compound C for 1 h dose-dependently blocked the activation of AMPK induced by irisin. The blockade of AMPK subsequently reversed irisin-induced reduction of cholesterol contents in hepatocytes isolated from both lean and DIO mice (Fig. 6b) . Again, triglyceride was not affected by irisin despite that it was dose-dependently increased by compound C (Fig. 6b) . Compound C at a dose of 10 μM was used in the rest of experiments. Consistently, compound C reversed the inhibitory effects of irisin on mRNA levels of Srebf2, Hmgcr and Hmgcs (Supplemental Fig. 3 ). As shown in Fig. 6c and d , blockade of AMPK activity by compound C completely attenuated the inhibition of SREBP2 nuclear translocation induced by irisin in the presence or absence of OA as revealed by Western blot analysis of the cytosolic and nuclear fractions of hepatocyte proteins and immunofluorescent staining. Consistently, knockdown of AMPKα1 abolished the repression of nuclear SREBP2 translocation (Fig. 7a ) and cholesterol accumulation (Fig. 7b ) evoked by irisin in HepG2 cells. Consistently, the inhibitory effect of irisin on mRNA expression of SREBF2, HMGCR and HMGCS was significantly blocked by inhibition of AMPK by AMPKα1 knockdown (Fig. 7c ). Therefore, blockade of irisin-induced activation of AMPK reversed its inhibition on SREBP2 nuclear translocation and subsequent suppression of cholesterol synthesis.
Discussion
Our study demonstrated that irisin could inhibit hepatic cholesterol synthesis via AMPK-dependent inhibition of SREBP2 and its downstream target genes. Irisin increased the phosphorylation of AMPKα in hepatocytes. Blockage of irisin-induced AMPK activation by compound C or knockdown of AMPKα1 reversed the suppressive effects of irisin on: 1) hepatic cholesterol synthesis; 2) mRNA expression of SREBP2 and its downstream target genes critical for cholesterol synthesis; and 3) nuclear translocalization of SREBP2.
Previous studies have indicated that irisin could improve dyslipidemia and hepatic steatosis in mice (Xiong et al., 2015) . The decrement of lipid accumulation in hepatocytes was proposed to result mainly from the suppression of triglyceride synthesis . In cultured AML12 hepatocytes, recombinant irisin significantly reduced the PA-induced lipid accumulation, and inhibited the PA-induced increase in lipogenic markers ACC and FAS at the mRNA and protein levels . Our studies identified suppression of cholesterol synthesis as an alternative pathway for irisin to reduce lipid content in hepatocytes. This conclusion is supported by following observations: 1) Administration of irisin reduced the hepatic lipid contents measured by Oil-red staining in lean and obese mice; 2) In mice and cultured hepatocytes, irisin decreased levels of hepatic cholesterol, while demonstrated no effect on triglyceride contents; 3) Irisin inhibited SREBP2 and its target genes HMGCS2 and HMGCR, a key transcriptional factor and the rate-limiting enzymes for cholesterol synthesis respectively; 4) The effects of irisin on genes related to triglyceride synthesis and βoxidation were negligible in hepatocytes. There exist two possible explanations for the conflicting observations: different cell models and sources of irisin used. In the studies by Park et al. (Park et al., 2015) , AML12 mouse hepatocyte cell line was used. This cell line expresses high levels of human transforming growth factor α (TGFα). Whether the high expression of TGFα in AML12 cells accounts for the distinct response to irisin remains to be explored. Theoretically, the preparation of irisin may affect its biological functions. This potential is unlikely because we observed no difference in the suppression of cholesterol synthesis between recombinant irisin-Fc and synthetic irisin.
While good progress has been made in identifying the physiological actions of irisin, its receptor and intracellular signaling pathway remains largely unknown. Previous studies have shown that irisin may activate AMPK, PI3K/AKT, or p38 MAPK and ERK Yang et al., 2015; Zhang et al., 2014; Lee et al., 2015) in skeletal muscle cells, hepatocytes and adipocytes. Our studies also suggest the presence of a functional receptor for irisin in hepatocytes. Activation of this receptor by irisin may stimulate AMPK activity, leading to the subsequent suppression of SREBP2 expression and nuclear translocalization. This observation is consistent with previous report demonstrating that AMPK could phosphorylate SREBP2 to reduce SREBP2 precursor cleavage and nuclear translocalization (Liu et al., 2015a) . Although activation of AMPK has been demonstrated to suppress hepatic lipid synthesis and to promote fatty acid β-oxidation by phosphorylating SREBP1c (Liu et al., 2015a; Ma et al., 2015; Elhanati et al., 2013; Samovski et al., 2015; Chen et al., 2014; Lee et al., 2012) , our studies did not detect consistent change in the levels of triglyceride, SREBP1c and its downstream target genes. A much higher dose of irisin may be required for its effect on triglyceride synthesis. Instead, SREBP2 transcription and nuclear translocalization in hepatocytes were significantly attenuated upon activation of AMPK by irisin. The molecular mechanism underlying the selection of SREBP2 over SREBP1 upon activation of irisin receptor in hepatocytes is currently unknown.
Emerging evidence has indicated that cross talks between organs are critical for energy homeostasis. The present studies suggest a direct communication between the skeletal muscle and liver via irisin. Our study also provides significant evidence that hepatocytes are targets for irisin in term of the regulation of hepatic cholesterol metabolism. Conditioned medium from C2C12 myocytes overexpressing FNDC5 significantly attenuated cholesterol synthesis in cultured hepatocytes. Other studies also support the concept that irisin may serve as an important cross-organ messenger linking skeletal muscle with the brain, adipose tissue and the cardiovascular system to integrate the exercise with the physiological activities in these organs (Wrann et al., 2013; Huh et al., 2014; Xiong et al., 2015; Song et al., 2014; Wu et al., 2015; Zhu et al., 2015; Zhang et al., 2015) . Importantly, irisin acts in concert with fibroblast growth factor 21 to promote adipocyte browning and thermogenesis in humans (Lee et al., 2014) . This result indicates that cross talk between skeletal muscle and adipose tissue may be critical for the control of adiposity. Taken together, all these observations suggest that irisin is an important molecule linking the skeletal muscle with the adipose tissue and liver to integrate lipid metabolism.
Despite the significant reduction in hepatic cholesterol, irisin at the dose used in the study demonstrates no effect on the insulin sensitivity in either lean or high fat diet induced obese mice. The mechanism underlying the dissociation effects of irisin on hepatic cholesterol and glucose metabolism is currently unknown. Whether the dose of irisin contributes to this discrepancy remains to be explored.
In conclusion, our studies indicate that irisin inhibits hepatic cholesterol synthesis via the mechanism dependent of AMPK-SREBP2 signaling. This finding may shed light on the treatment of diseases related to hypercholesterolemia, such as atherosclerosis. 
